Results 11 to 20 of about 1,098,931 (194)

Second-generation inhibitors of Bruton tyrosine kinase

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
doaj   +2 more sources

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +2 more sources

Synthesis and Biological Evaluation of Oxindole Sulfonamide Derivatives as Bruton\u27s Tyrosine Kinase Inhibitors [PDF]

, 2023
Bruton\u27s tyrosine kinase (BTK) is a promising molecular target for several human B-cell-related autoimmune disorders, inflammation, and haematological malignancies.
Marián , Hajdúch, Narendran , Annadurai, Chandra Prakash , Koraboina, Soňa , Gurská, Petr, Džubák, Venkatanarayana Chowdary , Maddipati, Rambabu , Gundla, Viswanath, Das   +7 more
core   +2 more sources

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases

Frontiers in Oncology, 2021
Vitreoretinal lymphoma (VRL) is a rare intraocular malignancy, and standard treatment approaches have not been defined yet. Bruton tyrosine kinase inhibitors are found to be effective in the treatment of primary central nervous system diffuse large B ...
Liang Wang, Wenxue Guan, Xiaoyan Peng
doaj   +1 more source

Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome

Frontiers in Immunology, 2022
Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy.
Yuehua Huang, Yanying Wang, Fan Yu, Xuehan Mao, Bianhong Wang, Jingxian Li, Lihong Li   +6 more
doaj   +1 more source

Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment [PDF]

eJHaem
Takafumi Tsushima, Nobue Sato, Yong‐Mei Guo, Hirotaka Nakamura, Kodai Kunisada, Song‐Gi Chi, Kenta Akie, Yuki Takahashi, Saki Nakamura, Kaoru Shimada, Genichiro Ishii, Yosuke Minami, Junichiro Yuda   +12 more
doaj   +2 more sources

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors

Frontiers in Immunology, 2021
Low-molecular weight chemical compounds have a longstanding history as drugs. Target specificity and binding efficiency represent major obstacles for small molecules to become clinically relevant. Protein kinases are attractive cellular targets; however,
Rula Zain, Rula Zain, Mauno Vihinen
doaj   +1 more source

Bing–Neel Syndrome: Update on Diagnosis and Treatment

Hemato, 2022
Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients diagnosed with ...
Evangeline Y. Wong, Shirley D’Sa, Monique C. Minnema, Jorge J. Castillo, Dipti Talaulikar   +4 more
doaj   +1 more source

A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context

, 2021
The use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of a number of hematological conditions is rapidly increasing. Ibrutinib is the most clinically advanced and common BTK inhibitor currently utilized.
Johnston, J, Mortimore, R, Robertson, I, Van Rooij, N   +3 more
core   +1 more source

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. [PDF]

J Cell Mol Med
Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B-cells. BTK inhibitors are approved in many hematologic malignancies: chronic lymphocytic leukaemia, mantle cell ...
Broccoli A, Del Re M, Danesi R, Zinzani PL.   +3 more
europepmc   +2 more sources